The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC).

Seth Andrew  Wander

Consulting or Advisory Role - AstraZeneca; Biovica; Foundation Medicine; Hologic; Lilly; Novartis; Pfizer; Puma Biotechnology; Veracyte

Speakers' Bureau - 2nd.MD; Guardant Health; Lilly; Novartis

Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics; Sermonix Pharmaceuticals

Salomon M.  Stemmer

Stock and Other Ownership Interests  - Can Fite Biopharma; CTG Pharma; DocBoxMD; VYPE

Research Funding - AstraZeneca/Merck; BioLineRx; Can Fite Biopharma; Halozyme; Moderna Therapeutics; Teva (Inst); Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Hope S.  Rugo

Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)

Seock-Ah  Im

Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech

Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Other Relationship - Roche

Peter Kar Han  Lau

Employment - George Clincal

Honoraria - Bristol-Myers Squibb; Lilly; MSD

Consulting or Advisory Role - Immunocore; MSD

Research Funding - Ambrx (Inst); AstraZeneca (Inst); Beigene (Inst); Bristol Myers Squibb (Inst); Gilead Sciences (Inst); Iksuda (Inst); Immunocore (Inst); Lilly (Inst); MSD (Inst); Olema Oncology (Inst); Pfizer (Inst); Pimera (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche/Genentech

Shani  Paluch-Shimon

Honoraria - ESMO, SPCC

Consulting or Advisory Role - AstraZeneca, Lilly, Roche, Pfizer, Novartis, Gilead, MSD, Daichi Sankyo, Stemline

Speakers' Bureau - AstraZeneca, Lilly, Roche, Pfizer, Novartis, Gilead

Research Funding - Shared Progress in Cancer Care – Pfizer independent research grant; Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Travel, Accommodations, Expenses - Gilead, Pfizer

Clélia  Cahuzac

Employment - Roche

Stock and Other Ownership Interests  - Roche

Research Funding - Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Annie  Collier

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Mona D.  Shah

Employment - Roche/Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Roche

Huy X.  Ngo

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Richard B.  Schwab

Employment - Genentech/Roche

Stock and Other Ownership Interests  - Biosplice (I)

Jing  Zhu

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Support for third-party writing assistance for this abstract, furnished by Brian Law, PhD, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Mafalda  Oliveira

Honoraria - AstraZeneca; Eisai Europe; Gilead Sciences; Lilly; Medscape; Pfizer; Roche; SeaGen

Consulting or Advisory Role - AstraZeneca; Cureo Science; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; iOne; ITeos Therapeutics; Lilly; MSD; Pfizer; Relay Therapeutics; Roche/Genentech; Seagen

Research Funding - AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)

Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Pierre Fabre

(OPTIONAL) Uncompensated Relationships - Head of the SOLTI Breast Cancer Research Group